New research has shown that the blood vessels that feed aggressive brain tumours have receptors that could allow a new type of drug-containing nanoparticle to be used to starve the tumours of the energy they use to grow and spread, and also cause other disruptions to their adapted existence, even killing themselves.

Scientists from the University of Nottingham and Duke University have discovered that many of the blood vessels that feed high-grade glioma brain tumours have high levels of Low-Density Lipoprotein (LDL) receptors (LDLR) on them. The findings pave the way for using drugs already in development at both institutions that could target these receptors and so be taken up by the tumours. The results have just been published in Pharmaceutics, in a new paper entitled, “Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High-Grade Glioma Amenable for Nanotherapeutic Delivery”

Gliomas are the most common primary brain tumours and originate from the glial cells of the brain. They are a heterogenous spectrum, from slow-growing to highly-aggressive infiltrating tumours. Nearly half of all Glioma’s are classed as high-grade gliomas (HGG) and, due to their highly aggressive nature, have a dismal prognosis with an average survival of only 4.6 months without treatment and approximately 14 months with today’s optimal multimodal treatments.

The researchers examined tissue microarrays from intra- and inter-tumour regions of 36 adult and 133 paediatric patients to confirm LDLR as a therapeutic target. Expression levels in three representative cell line models were also tested to confirm their future utility to test LDLR-targeted nanoparticle uptake, retention, and cytotoxicity. They showed widespread LDLR expression in adult and paediatric cohorts, and, importantly, also categorised the intra-tumour variation observed between the core and either rim or invasive regions of adult High-Grade Gliomas.

Dr Ruman Rahman from the University of Nottingham’s School of Medicine led the study and said: “Brain tumours can be very hard to treat with the current techniques available, this is because many of the drugs or nanoparticles that have been shown to work in cells, when used in tests of clinical treatments cannot penetrate the blood-brain barrier that many tumours sit behind. So, it’s vital we look for new ways to treat them. These findings are a significant step in understanding the biology of tumours and how they gather energy to grow and spread from the body’s own fat and protein-containing lipoprotein particles. The key now is to use drug and prodrug nanoparticles to target these receptors and cut off the energy supply of the cancer cells.”

David Needham, Professor of Translational Therapeutics in the School of Pharmacy at the University of Nottingham and Professor of Mechanical Engineering and Materials Science at Duke University has been working on developing new, more clinically-effective, formulations of a common metabolic inhibitor (niclosamide) that cuts off the energy of cells and could be modified as a treatment for a number of diseases – including cancer.

In its original anti-parasitic application, niclosamide has been used for over 60 years, taken as oral tablets, killing tapeworms on contact in the gut by inhibiting their crucial metabolic pathway and shutting down their energy supply. This same ability to lower the energy supply in a cell has shown that niclosamide can also reduce the energy a virus needs to replicate (another formulation Needham has recently been developing as a nasal spray and early treatment throat spray for COVID-19 and other respiratory virus infections. For the sprays, Needham figured out how to increase the solubility of niclosamide in simple pH-buffered solutions (Needham 2022, Needham 2023). However, niclosamide’s poor solubility in water makes it very difficult to use elsewhere, such as in an intravenous (i.v.) injection or infusion.

Professor Needham, who has been investigating this drug as a possible treatment for cancer for a number of years and has been driving research in this area and is co-author on this study, said: “We know that niclosamide works by turning down the dimmer switch on host cells in the body, like in the nose as a preventative for COVID19 and other infections.  Cancer’s though have developed additional strategies to survive and so have very different metabolic processes than normal cells.  Niclosamide targets not only the energy production in the cells but also triggers other processes that result in what is called, Apoptosis, (self-killing) in the cells.  And now we know that brain tumours have LDL receptors that we think are used to feed their growth and meastatic spread we can work to modify the drug to target these and starve the cancer cells of their energy. Given that cancers feed on LDLS our strategy is to make the drug look like the cancer’s food.” 

Professor Needham and the team at Duke have developed the “Bricks to Rocks Technology” (B2RT) that makes this common low solubility drug (commonly called “brick dust”) into even less soluble “rocks” for the expressed purpose of making pure prodrug nanoparticles. They converted niclosamide into a new less soluble (niclosamide stearate) prodrug that allows the formation of the injectable or implantable nanoparticles.  With data already obtained showing that the, so-called “niclosamide stearate prodrug therapeutic” (NSPT) can stop the formation of lung metastases in a mouse model of Osteosarcoma (Reddy, Kerr et al. 2020), and also actually cure some dogs in a small canine feasibility study (Eward, Needham et al. 2023). 

Professor Needham continues: “This technology is now ready to be applied in other cancers, and Nottingham is ideally placed to develop this with the expertise at the Children’s Brain Tumour Research Centre. The next step will be to test the B2RT with Ruman and colleagues specifically in brain tumour cells, animal models and, if it shows promise, move it into patients as fast as feasibly and safely as possible.  We want to determine if and to what extent LDLR-targeted anti-cancer drug and prodrug nanoparticles can have activity in brain cancer, both injected intravenously and/or as post-surgical deposits.”

Such LDLR-targeted nanoparticles have already been developed as a feasible formulation by another School of Pharmacy researcher, Jonathan Burley and his recent PhD graduate George Bebawy who showed that they improved tumour cell uptake.  

Professor Needham adds: “We are now actively seeking industry and also government and infectious disease institute partners to help pursue preclinical and eventually clinical trials. We’re keen to hear from anyone who thinks they can help to further the testing and development of this new technology.”

Source: University of Nottingham